Monoclonal IgG4/2κ Deposition Following Eculizumab Therapy for Recurrent Atypical Hemolytic Uremic Syndrome in Kidney Transplantation

Eculizumab is an emerging therapy for atypical hemolytic uremic syndrome (aHUS). Early identification and treatment of recurrent aHUS after kidney transplantation requires a high clinical suspicion but results in improved graft function and patient outcome. We present a patient who developed recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Priyamvada, Chen, Hui, Gordon, Craig E., Ghai, Sandeep, Sloan, J. Mark, Quillen, Karen, Moradi, Sara, Chitalia, Vipul, Gautam, Amitabh, Henderson, Joel, Francis, Jean M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380410/
https://www.ncbi.nlm.nih.gov/pubmed/32734194
http://dx.doi.org/10.1016/j.xkme.2019.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380410/
https://www.ncbi.nlm.nih.gov/pubmed/32734194
http://dx.doi.org/10.1016/j.xkme.2019.03.005

Ejemplares similares